Customer Center
Login | Register

VERIGENE® BLOODSTREAM INFECTION TESTS

VERIGENE® Bloodstream Infection Tests

Rapid and accurate identification of infection causing bacteria & resistance to commonly used antibiotics helps ensure a patient receives the right therapy at the right time

What is Sepsis?

 

Sepsis is a life-threatening response to bacteria in the bloodstream. It is responsible for 1.6 million hospitalizations and nearly 200,000 deaths per year in the United States.1,2 It costs the U.S. healthcare system more than $20 billion per year3 and is commonly complicated by antimicrobial resistance.

 

Time is of the Essence

 

Earlier diagnosis of sepsis leads to better outcomes, as the risk of death increases by 7.6% every hour that appropriate treatment is delayed. Targeted therapy based on identification of causative bacteria and antibacterial resistance is the most effective sepsis treatment.4

 

Conventional diagnostic methods require 48 to 96 hours to deliver bacterial identification and resistance determination. In the meantime, patients are treated with broad-based antibiotics that are often unnecessary or inappropriate and frequently toxic.

 

Tests run on the VERIGENE platform are designed to target infections in the bloodstream, respiratory tract, and gastrointestinal tract.

The VERIGENE Difference

 

 

VERIGENE provides cost-effective bacterial identification and antibiotic resistance determination directly from positive blood culture bottles up to 48 hours faster than conventional methods.5 The Gram-Positive Blood Culture (BC-GP) test provides 15 different targets, and the Gram-Negative Blood Culture (BC-GN) test provides 14 different targets.

 

VERIGENE enables an earlier shift from empiric to targeted antibiotic treatment6 and differentiates potential blood culture contaminants. As a result, the VERIGENE System delivers better outcomes, improved patient care, and true antibiotic stewardship, all at a lower cost.


GRAM-POSITIVE BLOOD CULTURE

The VERIGENE® Gram-Positive Blood Culture Test (BC-GP) identifies genus, species, and genetic resistance determinants for a broad panel of gram-positive bacteria directly from positive blood culture bottles.
 
Read More

GRAM-NEGATIVE BLOOD CULTURE

The VERIGENE® Gram-Negative Blood Culture Test (BC-GN) identifies genus, species, and genetic resistance determinants for a broad panel of gram-negative bacteria directly from positive blood culture bottles.
 
Read More


Luminex Corporation is a partner of Sepsis Alliance

 
Luminex Corporation is a partner of Sepsis Alliance

References:

  1. Healthcare Cost and Utilization Project. Statistical Brief #122. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb122.pdf. Accessed December 22, 2013.
  2. Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., Pinsky, M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 Jul;29(7):1303-10.
  3. Healthcare Cost and Utilization Project. Statistical Brief #160. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb160.pdf. Accessed November 4, 2013.
  4. Kumar A, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
  5. Buchan BW, Ginocchio CC, Manii R, Cavagnolo R, Pancholi P, et al. (2013) Multiplex Identification of Gram-Positive Bacteria and Resistance Determinants Directly from Positive Blood Culture Broths: Evaluation of an Automated Microarray-Based Nucleic Acid Test. PLoS Med 10(7): e1001478. doi:10.1371/journal.pmed.1001478.
  6. Performance of the VERIGENE gram-positive blood culture assay for direct detection of gram-positive organisms and resistance markers in a pediatric hospital. J Clin Microbiol. 2014 Jan;52(1):283-7. doi: 10.1128/JCM.02322-13. Epub 2013 Oct 16.

 

For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.